All In Biotech

Drug Trial Radar · NCT01744223

Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant

A Phase 1/2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells After Partially Mismatched, Related, T Cell-Depleted HSCT (Hematopoietic Stem Cell Transplant)

Last checked: Nov 19, 2026Latest source record: Jul 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Mar 2013

Primary completion

Oct 9, 2019

Study completion Oct 2032

Sponsor

Lead sponsor
Bellicum PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Dec 6, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate patients with blood cell cancers who are going to have an allogeneic (donor) blood stem cell transplant from a partially matched relative. The research study will test whether immune cells, called T cells, which come from the donor relative and are specially grown in the laboratory and then given back to the patient along with the stem cell transplant (T cell addback), can help the immune system recover faster after the transplant. As a safety measure, these T cells have been "programmed" with a "self-destruct switch" so that if, after they have been given to the patient, the T cells start to react against the tissues (called "graft versus host" disease, GVHD), the T cells can be destroyed.

Conditions

  • Acute Lymphoblastic Leukemia
  • Acute Myelogenous Leukemia
  • Lymphoma
  • Myelodysplastic Syndromes

Interventions

  • BPX-501 dose 1Biological

    Subjects will receive 2x10E5 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.

  • RimiducidDrug

    Dimerizer drug administered by intravenous infusion in those subjects who develop GVHD after infusion of BPX-501 cells.

  • BPX-501 dose 2Biological

    Subjects will receive 5x10E5 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.

  • BPX-501 dose 3Biological

    Subjects will receive 1x10E6 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.

  • BPX-501 dose 4Biological

    Subjects will receive 3x10E6 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.

  • SCTProcedure

    all subjects will receive an alpha beta depleted donor transplant as part of treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. BPX-501 SafetyTime frame: 24 months
  2. Rimiducid SafetyTime frame: 24 months
  3. MTDTime frame: 24 months
  4. Immune ReconstitutionTime frame: 24 months

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Emory University Winship Cancer Institute

    Atlanta, Georgia

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • University Hospitals of Cleveland

    Cleveland, Ohio

  • Oregon Health & Science University

    Portland, Oregon

  • Baylor Sammons Cancer Center

    Dallas, Texas

  • UT Southwestern Medical Center

    Dallas, Texas

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.